Q-omics provides the consensus-scored PRAMEF8 profile across patient tissues and cancer cell-line models. PRAMEF8 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PRAMEF8 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, PRAMEF8 RNA expression shows 6,421 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, LIHC, and TGCT as cancer lineages where PRAMEF8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMEF8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMEF8 survival associations across molecular data types. PRAMEF8 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMEF8 RNA expression–survival associations across cancer types. High PRAMEF8 expression shows unfavorable associations in STAD, BLCA, CESC, SKCM, THYM and PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .020). Together, the overview and detailed table identify STAD as the clearest survival context for PRAMEF8 RNA expression.
This table summarizes PRAMEF8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRAMEF8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAMEF8 shows higher tumor expression in LIHC and BRCA. The LIHC box plot shows higher PRAMEF8 RNA expression in tumor versus normal tissue (log2 FC = +0.196, t-test p = .030).
This table shows molecular features associated with PRAMEF8 in patient tissues and cancer cell lines. In patient samples, PRAMEF8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAMEF8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
